Biogen Idec sells BENLYSTA royalty rights to DRI Capital managed fund
10 September 2012 | By Biogen Idec
Biogen Idec has sold to a DRI Capital managed fund its royalty and other rights relating to BENLYSTA®...
List view / Grid view
10 September 2012 | By Biogen Idec
Biogen Idec has sold to a DRI Capital managed fund its royalty and other rights relating to BENLYSTA®...
17 August 2012 | By Biogen Idec
New collaboration in support of Science, Technology, Engineering, and Math education...
17 July 2012 | By Biogen Idec
Labs at Duke University and HudsonAlpha Institute to lead research consortium...
5 July 2012 | By Biogen Idec
Biogen Idec and SOBI announced the initiation of two global pediatric clinical trials...
29 June 2012 | By Biogen Idec
Isis expands its rare disease franchise to include DM1...
30 May 2012 | By Biogen Idec
Biogen Idec will join with the MS community around the world...
18 May 2012 | By Biogen Idec / Elan Corporation plc
Use of biomarker has potential to advance personalised treatment for MS patients...
14 May 2012 | By Biogen Idec
Two new dosing innovations designed to help patients receiving once-a-week AVONEX...
9 May 2012 | By Biogen Idec
U.S. and EU regulatory authorities have accepted marketing applications for review...
28 February 2012 | By
Dosing enhancements may improve treatment experience for patients receiving AVONEX® (interferon beta-1a) for MS...
28 February 2012 | By Biogen Idec
EMA submission anticipated within the coming days...
27 February 2012 | By Biogen Idec
Samsung Biologics & Biogen Idec have established their joint venture...
14 February 2012 | By Biogen Idec
Biogen Idec and Stromedix, Inc. announced that they have entered into a definitive agreement under which Biogen Idec will acquire Stromedix Inc...
30 January 2012 | By Biogen Idec
Kenneth DiPietro named Executive Vice President, Human Resources...
26 January 2012 | By Biogen Idec
Biogen Idec and Elan Corporation, plc announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for SPMS...